Innovative Collaborations BACHEM AG actively partners with biotech and pharma companies like TIRmed Pharma and SpheriTech to develop advanced therapeutic solutions such as oligonucleotide therapies and water-based peptide synthesis. These collaborations open opportunities to offer specialized chemicals, custom synthesis services, and collaborative R&D support for similar emerging biotech projects.

Expansion & Investment With recent facility expansions in Switzerland and ambitious sales targets exceeding CHF 1 billion by 2026, BACHEM is investing heavily in infrastructure and manufacturing capacity. Sales opportunities exist in providing high-quality chemical raw materials, process optimization tools, and technical services to support their growth and new plant operations.

Market Trends in Sustainability BACHEM’s focus on water-based peptide synthesis to replace organic solvents highlights a commitment to environmentally friendly manufacturing. Companies offering eco-friendly chemical solutions, sustainable intermediates, or regulatory-compliant raw materials can position themselves as strategic partners aligned with BACHEM’s sustainability initiatives.

Leadership & Strategic Growth The appointment of a new CEO and key operational hires like the COO indicates strategic transformation aimed at scaling revenues and margins. This leadership transition provides an opportunity to engage with top decision-makers by demonstrating how advanced chemicals, process efficiencies, or digital solutions can support BACHEM’s growth objectives.

Technology Integration BACHEM’s utilization of advanced tech stacks such as Salesforce, STARLIMS, and Module Federation reflects their focus on digital transformation and operational excellence. Solutions that enhance pharmaceutical and chemical R&D workflows, data management, or automation could be highly valuable for streamlining BACHEM’s internal processes and maintaining innovation leadership.